Company: APXIF
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065703
Chunk: 367

Company: APx Acquisition Corp. I
Filing Date: 2025-07-18
Form: F-4/A
Chunk 367
---
 independently rather than relying on our e -commerceplatform or internal genetic nutritionist services. This indicated organic market demand for a partner -baseddistribution model and a B2B2C distribution strategy. To support the shift to B2B2C, we streamlined operations by consolidating Rewell and Heritas Diagnostics under a unified structure and significantly downsized DTC -relatedfunctions, such as digital marketing, logistics, digital product design, and customer success management. As a result, our employee count was reduced from 49 as of June30, 2024, to 25 as of the date of this registration statement of which this prospectus is part, primarily impacting roles tied to the Rewell DTC operations. All Rewell products previously sold directly to consumers, including the Continuous Evolution Kit, will continue to be available through our network of B2B2C partners. These partners are responsible for the commercialization of the kits, the collection of samples, and, in many cases, the delivery of interpretation services. While the delivery mechanism has changed, the core service that offers the combination of genetic and microbiome testing with personalized health recommendations remains fundamentally the same. The transition away from DTC was executed in a phased and structured manner: • Closure of E -Commerce Operations.We began a gradual wind -downof our e -commercechannel in early 2025, including removing the ability to place new orders directly through our platform. While customers could no longer purchase products directly, existing users continued to have access to our services. • Customer Support Continuity.Existing DTC customers received full product support to complete their user journey, including access to our digital platform and consultations with certified genetic nutritionists, until all obligations were fully met. • Reallocation of Resources.We eliminated or reassigned resources to align more closely with the B2B2C model, ensuring operations better supported the transition. • Product Development.We communicated the operational changes to stakeholders and began working with potential B2B2C partners to map out the new customer journey and refine the experience. While discussions with potential partners have been initiated, we have not yet entered into any formal commercial agreements under the new model, which remains in development. Nonetheless, we believe that the B2B2C model will facilitate more efficient scaling with lower operational costs, broader geographic reach, and deeper market penetration through trusted local partners. 181 Our Operating Segments We operate across two segments within our corporate structure, dedicated to providing precise and secure biological data to empower individuals to make informed health choices. Our business